Clinical trial · Interventional
Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma
Randomisierte Phase II Studie Zum Einsatz Von Goserelin Und Oralen Kontrazeptiva Zur Reduktion Ovarieller Toxizitäten während Zytostatischer Primärtherapie Bei Fertilen Patientinnen Mit Hodgkin Lymphom in Fortgeschrittenen Stadien
NCT01014507CI-TRIAL-00007254PROFEcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is designed to test the the protective capacity of Goserelin compared with oral contraceptive
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkins Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 8 cycles BEACOPPesc plus Goserelin | Drug | — | UNRESOLVED |
| 8 cycles BEACOPPesc plus oral contraceptive | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- A
- interventionNames
- Drug: 8 cycles BEACOPPesc plus oral contraceptive
- type
- EXPERIMENTAL
- label
- B
- interventionNames
- Drug: 8 cycles BEACOPPesc plus Goserelin
Primary outcomes (1)
- measure
- FSH level 6 month after end of treatment
- timeFrame
- 6 month
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced stage Hodgkins Lymphoma (histologically proven) * Normal FSH-levels * Written informed consent Exclusion Criteria: * Hodgkins Lymphoma as "composite lymphoma" * Primary ovarial dysfunction * Age \> 40
References
Publications (1)
- RESULTBehringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010 Oct;21(10):2052-2060. doi: 10.1093/annonc/mdq066. Epub 2010 Mar 19. PMID 20305034